Looks like we on the move, page-25

I’ll give you a case in point. MVP- Penthrox.
A non-opioid drug proven to work effectively for acute, short term pain relief in trauma in hospitals and ambulances for 40+ years in Australia.
Trials upon trials, years of evidence of effective indicated use.
Many critical care Doctors vouch for it and can’t believe that it isn’t used far more extensively throughout hospitals globally, with the opioid epidemics.
It has successfully launched into 9 of 37 countries in Europe and awaiting a further 22 countries to launch into, including China, USA, and Russia.
Many of the European approvals occurred at least 12 months or more ago and sales penetration is still significantly shallow and not yet Exponential.
Eg. Regulatory variations have caused delays in Europe to many of these countries, labelling challenges, awaiting approvals within different individual segments such as implementation into ambulances’ guidelines etc etc.

Its a huge process of penetration into each individual department, medical segement, and jurisdiction in other words.
Red tape after red tape, regulatory variations are always a hurdle to having these great solution drugs impacting on the sales sheet.

Hope that explains a little more specifically.